The capacity of group V sPLA2 to increase atherogenicity of ApoE-/- and LDLR-/- mouse LDL in vitro predicts its atherogenic role in vivo

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 29, Issue 4, 2009, Pages 532-538

  Boyanovsky, Boris ^a   Zack, Melissa ^b   Forrest, Kathy ^a   Webb, Nancy R ^a,b,c  

^a Cardiovascular Research Center   (United States)

^b UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

^c UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Atherosclerosis; Cholesterol ester; Foam cells; Sphingomyelin

Indexed keywords

APOLIPOPROTEIN E; COLLAGEN; LIPID; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR; PHOSPHATIDYLCHOLINE; SECRETORY PHOSPHOLIPASE A2; PHOSPHOLIPASE A2 GROUP V; PLA2G5 PROTEIN, MOUSE; SPHINGOMYELIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CONTROLLED STUDY; FEMALE; FOAM CELL; HYDROLYSIS; IN VITRO STUDY; IN VIVO STUDY; MACROPHAGE; MALE; MOUSE; NONHUMAN; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; ANIMAL; AORTA; C57BL MOUSE; CELL CULTURE; DISEASE MODEL; ENZYMOLOGY; FAT INTAKE; GENETICS; METABOLISM; MOUSE MUTANT; PATHOLOGY; TIME;

ANIMALS; AORTA; APOLIPOPROTEINS E; ATHEROSCLEROSIS; CELLS, CULTURED; COLLAGEN; DIETARY FATS; DISEASE MODELS, ANIMAL; FEMALE; FOAM CELLS; GROUP V PHOSPHOLIPASES A2; HYDROLYSIS; LIPOPROTEINS, LDL; MACROPHAGES, PERITONEAL; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PHOSPHATIDYLCHOLINES; RECEPTORS, LDL; SPHINGOMYELINS; TIME FACTORS;

EID: 63449133692     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/ATVBAHA.108.183038     Document Type: Article

References (35)

1. Lambeau G, Gelb MH. Biochemistry and Physiology of Mammalian Secreted Phospholipases A2. Annu Rev Biochem. 2008;77:495-520.
2. Kimura-Matsumoto M, Ishikawa Y, Komiyama K, Tsuruta T, Murakami M, Masuda S, Akasaka Y, Ito K, Ishiguro S, Morita H, Sato S, Ishii T. Expression of secretory phospholipase A2s in human atherosclerosis development. Atherosclerosis. 2008;196:81-91.
3. Murakami M, and Kudo I. New phospholipase A(2) isozymes with a potential role in atherosclerosis. Curr Opin Lipidol. 2003;14:431-436.
4. Webb NR. Secretory phospholipase A2 enzymes in atherogenesis. Curr Opin Lipidol. 2005;16:341-344.
5. Hurt-Camejo E, Camejo G, Peilot H, Oorni K, Kovanen P. Phospholipase A2 in Vascular Disease. Circ Res. 2001;89:298-304.
6. Gesquiere L, Cho W, Subbaiah PV. Role of group IIa and group V secretory phospholipases A(2) in the metabolism of lipoproteins. Substrate specificities of the enzymes and the regulation of their activities by sphingomyelin. Biochemistry. 2002;41:4911-4920.
7. Wooton-Kee CR, Boyanovsky BB, Nasser MS, de Villiers WJ, Webb NR. Group V sPLA2 hydrolysis of low-density lipoprotein results in spontaneous particle aggregation and promotes macrophage foam cell formation. Arterioscler Thromb Vasc Biol. 2004;24:762-767.
8. Hanasaki K, Yamada K, Yamamoto S, Ishimoto Y, Saiga A, Ono T, Ikeda M, Notoya M, Kamitani S, Arita H. Potent modification of low density lipoprotein by group X secretory phospholipase A2 is linked to macrophage foam cell formation. J Biol Chem. 2002;277:29116-29124.
9. Sato H, Kato R, Isogai Y, Saka G-i, Ohtsuki M, Taketomi Y, Yamamoto K, Tsutsumi K, Yamada J, Masuda S, Ishikawa Y, Ishii T, Kobayashi T, Ikeda K, Taguchi R, Hatakeyama S, Hara S, Kudo I, Itabe H, Murakami M Analyses of group III secreted phospholipase A2 transgenic mice reveals potential participation of this enzyme in plasma lipoprotein modification, macrophage foam cell formation, and atherosclerosis. J Biol Chem. 2008;283:33483-33497.
10. Boyanovsky BB, van der Westhuyzen DR, Webb NR. Group V secretory phospholipase A2-modified low density lipoprotein promotes foam cell formation by a SR-A- and CD36-independent process that Involves cellular proteoglycans. J Biol Chem. 2005;280:32746-32752.
11. Bostrom MA, Boyanovsky BB, Jordan CT, Wadsworth MP, Taatjes DJ, de Beer FC, Webb NR. Group V secretory phospholipase A2 promotes atherosclerosis: evidence from genetically altered mice. Arterioscler Thromb Vasc Biol. 2007;27:600-606.
12. Zhao Z, de Beer MC. Cai L, Asmis R, de Beer FC, de Villiers WS, van der Westhuyzen DR. Low-density lipoprotein from apolipoprotein E-deficient mice induces macrophage lipid accumulation in a CD36 and scavenger receptor class A-dependent manner. Arterioscler Thromb Vasc Biol. 2005;25:168-173.
13. Jeong T, Schissel SL. Tabas I, Pownall HJ, Tall AR, Jiang X. Increased sphingomyelin content of plasma lipoproteins in apolipoprotein E knockout mice reflects combined production and catabolic defects and enhances reactivity with mammalian sphingomyelinase. J Clin Invest. 1998;101:905-912.
14. Koumanov K, Wolf C, Bereziat G. Modulation of human type II secretory phospholipase A2 by sphingomyelin and annexin VI. Biochem J. 1997;326:227-233.
15. Singh DK, Gesquiere LR, Subbaiah PV. Role of sphingomyelin and ceramide in the regulation of the activity and fatty acid specificity of group V secretory phospholipase A2. Arch Biochem Biophys. 2007;459:280-287.
16. Kuksis A, Pruzanski W. Phase composition of lipoprotein sphingomyelin/cholesterol/PtdCho affects fatty acid specificity of sPLA2s. J Lipid Res. 2008:9:2161-2168.
17. Febbraio M, Abumrad NA, Hajjar DP, Sharma K, Cheng W, Pearce SFA, Silverstein RL. A null mutation in murine CD36 reveals an important role in fatty acid and lipoprotein metabolism. J Biol Chem. 1999;274:19055-19062.
18. Ishiguro K, Kadomatsu K, Kojima T, Muramatsu H, Tsuzuki S, Nakamura E, Kusugami K, Saito H, Muramatsu T. Syndecan-4 deficiency impairs focal adhesion formation only under restricted conditions. J Biol Chem. 2000;275:5249-5252.
19. Satake Y, Diaz BL, Balestrieri B, Lam BK, Kanaoka Y, Grusby MJ, Arm JP. Role of group V phospholipase A2 in zymosan-induced eicosanoid generation and vascular permeability revealed by targeted gene disruption. J Biol Chem. 2004;279:16488-16494.
20. -/- mice. Arterioscler Thromb Vasc Biol. 2002;22:456-461.
21. Webb NR, Bostrom MA, Szilvassy SJ, van der Westhuyzen DR, Daugherty A, de Beer FC. Macrophage-expressed Group IIA sPLA2 increases atherosclerotic lesion formation in LDL receptor-deficient mice. Arterioscler Thromb Vasc Biol. 2003;23:263-268.
22. Pruzanski W, Lambeau L, Lazdunsky M, Cho W, Kopilov J, Kuksis A. Differential hydrolysis of molecular species of lipoprotein phosphatidylcholine by groups IIA, V and X secretory phospholipases A2. Biochim Biophys Acta. 2005;1736:38-50.
23. Boyanovsky BB, Shridas P, Simons M, van der Westhuyzen DR, Webb NR Syndecan-4 mediates macrophage uptake of group V secretory phospholipase A2-modified low density lipoprotein. J Lipid Res. 2008 epub.
24. Flood C, Gustafsson M, Pitas RE, Arnaboldi L, Walzem RL, Boren J. Molecular mechanism for changes in proteoglycan binding on compositional changes of the core and the surface of low-density lipoproteincontaining human apolipoprotein B100. Arterioscler Thromb Vasc Biol. 2004;24:564-570.
25. Febbraio M, Podrez EA, Smith JD, Hajjar DP, Hazen SL, Hoff HF, Sharma K, Silverstein RL. Targeted disruption of the class B scavenger receptor CD36 protects against atherosclerotic lesion development in mice. J Clin Invest. 2000;105:1049-1056.
26. Febbraio M, Guy E, Silverstein RL. Stem cell transplantation reveals that absence of macrophage CD36 is protective against atherosclerosis. Arterioscler Thromb Vasc Biol. 2004;24:2333-2338.
27. Guy E, Kuchibhotla S, Silverstein R, Febbraio M. Continued inhibition of atherosclerotic lesion development in long term Western diet fed CD36°/apoE° mice. Atherosclerosis. 2007;192:123-130.
28. Marleau S, Harb D, Bujold K, Avallone R, Iken K, Wang Y, Demers A, Sirois MG, Febbraio M, Silverstein RL, Tremblay A, Ong H EP 80317, a ligand of the CD36 scavenger receptor, protects apolipoprotein E-deficient mice from developing atherosclerotic lesions. FASEB J. 2005: 04-3253fje.
29. Moore KJ, Kunjathoor VV, Koehn SL, Manning JJ, Tseng AA, Silver JM, McKee M, Freeman MW. Loss of receptor-mediated lipid uptake via scavenger receptor A or CD36 pathways does not ameliorate atherosclerosis in hyperlipidemic mice. J Clin Invest. 2005;115:2192-2201.
30. Webb NR, Moore KJ. Macrophage-derived foam cells in atherosclerosis: lessons from murine models and implications for therapy. Curr Drug Targets. 2007;8:1249-1263.
31. Moore KJ, Freeman MW. Scavenger receptors in atherosclerosis: beyond lipid uptake. Arterioscler Thromb Vasc Biol. 2006;26:1702-1711.
32. Manning-Tobin JJ, Moore KJ, Seimon TA, Bell SA, Sharuk M, Alvarez-Leite JI, de Winther MPJ, Tabas I, Freeman MW. Loss of SR-A and CD36 activity reduces atherosclerotic lesion complexity without abrogating foam cell formation in hyperlipidemic mice. Arterioscler Thromb Vasc Biol. 2009;9:19-26.
33. Ghesquiere SAI, Gijbels MJJ, Anthonsen M, van Gorp PJJ, van der Made I, Johansen B, Hofker MH, de Winther MPJ. Macrophage-specific overexpression of group IIa sPLA2 increases atherosclerosis and enhances collagen deposition. J Lipid Res. 2005;46:201-210.
34. Tietge UJF, Maugeais C, Cain W, Grass D, Glick JM, de Beer FC, Rader DJ. Overexpression of secretory phospholipase A2 causes rapid catabolism and altered tissue uptake of high density lipoprotein cholesteryl ester and apolipoprotein A-I. J Biol Chem. 2000;275:10077-10084.
35. -/- mice between pravastatin and the sPLA2 inhibitor varespladib (A-002). J. Lipid Res. In press.